About

Dr. Sutthichai Sae-Tia, MD, is a Clinical Associate Professor in Medicine at Stony Brook University. He specializes in Infectious Diseases and is affiliated with Stony Brook Internists - Infectious Disease located in Lake Grove, NY. Dr. Sae-Tia completed his medical education at Ramathibodi Hospital Faculty of Medicine in 1999. He further advanced his training with fellowships at Johns Hopkins University in Transplant Oncology Infectious Disease in 2018 and at Thomas Jefferson University Hospitals in Infectious Disease in 2008. His residency was completed at UPMC McKeesport in General Medicine in 2006. He is board-certified in Infectious Disease and Internal Medicine by the American Board of Internal Medicine. Dr. Sae-Tia's expertise and academic role focus on infectious diseases, contributing to the clinical and educational missions of Stony Brook Medicine.

Research topics

• Biology
• Microbiology
• Genetics
• Internal medicine
• Virology
• Medicine
• Immunology

Selected publications

• Susceptibility of nucleotide-binding oligomerization domain 2 mutations to Whipple’s disease

  Lara D. Veeken · 2023 · 6 citations

  • Medicine
  • Immunology
  • Internal medicine

  OBJECTIVES: Whipple's disease (WD) results from infection of the bacteria Tropheryma whipplei (TW). This disease is characterized by macrophage infiltration of intestinal mucosa and primarily affects Caucasian males. Genetic studies of host susceptibility are scarce. Nucleotide-binding oligomerization domain containing protein 2 (NOD2) is an innate immune sensor, resides mainly in monocytes/macrophages and contributes to defence against infection and inflammatory regulation. NOD2 mutations are associated with autoinflammatory diseases. We report the association of NOD2 mutations with TW and WD for the first time. METHODS: A multicentre, retrospective study of three patients with WD was conducted. Patients received extensive multidisciplinary evaluations and were cared for by the authors. NOD2 and its association with infection and inflammation were schematically represented. RESULTS: All patients were Caucasian men and presented with years of autoinflammatory phenotypes, including recurrent fever, rash, inflammatory arthritis, gastrointestinal symptoms and elevated inflammatory markers. All patients underwent molecular testing using a gene panel for periodic fever syndromes and were identified to carry NOD2 mutations associated with NOD2-associated autoinflammatory disease. Despite initially negative gastrointestinal evaluations, repeat endoscopy with duodenal tissue biopsy ultimately confirmed WD. After initial ceftriaxone and maintenance with doxycycline and/or HCQ, symptoms were largely controlled, though mild relapses occurred in follow-up. CONCLUSION: Both NOD2 and TW/WD are intensively involved in monocytes/macrophages. WD is regarded as a macrophage disease. NOD2 leucin-rich repeat-associated mutations in monocytes/macrophages cause functional impairment of these cells and consequently may make the host susceptible for TW infection and WD, especially in the setting of immunosuppression.

  PublisherDOI

• Cryptogenic Liver Abscess Caused by a K1 Serotype Klebsiella pneumoniae Isolate

  Journal of Global Infectious Diseases · 2022-07-01 · 1 citations

  articleOpen accessSenior author

  Hypervirulent Klebsiella pneumoniae (hv Kp ) is a common cause of pyogenic liver abscesses in Asia but is quite uncommon in North America. Among the cases described in North America, only occasional reports have described molecular strain typing to confirm the K1 strain as the causative agent. We report a 56-year-old Hispanic female with no previous intra-abdominal pathology and no recent travel, who presented with subacute abdominal pain and developed bacteremia and monomicrobial pyogenic liver abscess due to a community-acquired K1 serotype K. pneumoniae isolate. In this case, the infection was recognized early, so the patient was successfully treated with percutaneous drainage and prolonged antibiotic therapy. Hv kp can cause severe invasive disease with high morbidity and mortality, and the recent emergence of multidrug resistance in these strains poses a serious threat to public health. In addition, the isolation of a K1 K. pneumoniae strain from a cryptogenic liver abscess in a Hispanic patient with no epidemiologic risk factors raises concern for a wider spread of the hypervirulent strain beyond Asian populations. Therefore, a high index of suspicion for hv Kp infection in the Hispanic population can be crucial as the hypervirulent strain is likely to cause severe metastatic infection with significant morbidity and mortality.

  PublisherDOI

• 348. Characteristics and Outcomes in Hospitalized Patients with Covid-19 Complicated by Fungemia: A Single Center Retrospective Study

  Open Forum Infectious Diseases · 2021-11-01 · 1 citations

  articleOpen accessSenior author

  Abstract Background Covid19 caused by SARS-CoV2 can lead to significant morbidity and mortality. Fungemia is a rare hospital-associated infection and there are limited data regarding its association with Covid19. We reviewed all cases of fungemia in our Covid19 cohort at Stony Brook University Hospital (SBUH). Methods We conducted a retrospective medical record review of patients admitted with Covid19 in a 3-month interval. We reviewed positive blood cultures for fungi and recorded co-morbidities, co-infections, length of stay, treatments, and outcomes (survival vs death). There were 60 positive blood cultures for fungi in 25 unique patients (Table 1); in prior years < 30 per year reported at SBUH. Table 1. Fungal Blood Cultures Collation of each unique identified fungal species from fungal blood cultures in patients hospitalized with Covid-19 Results During a 3 month interval at the local peak of the pandemic 1398 patients hospitalized with Covid19 at SBUH, 25 cases of fungemia were detected; C. albicans (CA) n=8,32%, non C albicans species (nCA) n=16,64%, and C. neoformans n=1,4%, 17/25 (68%) also with bacteremia during same hospitalization. In same 3 months there were 264 cases of bacteremia and Covid19 co-infection. Demographics and medical co-morbidities of fungemic patients are in Table 2. Majority were men (76%). No difference between fungaemic (FC) and total cohort (TC) in median age (62 vs 62), DM p=0.31, HTN p=1.0, COPD p=0.12. Within FC, DM was higher in nCA group (58.8%) vs CA group (37%). Mortality was 40% in FC vs 15% in TC, p< 0.001. Within FC mortality was 56% in nCA and 25% in CA group. C. parapsilosis was the most common nCA species isolated with 43% mortality. FC more likely to require ICU and mechanical ventilation (88% vs 15%, p< 0.0001) and had longer median length of stay 42 days vs 22 days. The median time from admission to fungaemia was 21d, from central line placement 19d, Table 3. Of FC 21 (84%) were treated with steroids/Tocilizumab concurrently. Of note, no mortality was recorded in the 4 patients that did not receive steroids/Tocilizumab. PCT and WBC were significantly higher at time of fungemia as compared to admission, Table 3. Table 2, Patient co-morbidities and hospitalization stay characteristics Co-morbidities and requirement for ICU stay, mechanical ventilation for total cohort Covid-19 and fungemic cohort Table 3, Patient Characteristics and Laboratory Parameters Relevant patient characteristics and laboratory parameters in patients hospitalized with Covid19 and fungemia Conclusion Fungemia in hospitalized patients with COVID-19 is associated with higher mortality. We observed higher fatality in non C. albicans infections. Prolonged use of central line catheters and concurrent treatment with steroids/tociluzimab are likely high-risk factors for development of fungemia. Disclosures All Authors: No reported disclosures

  PublisherOA PDFDOI

• Genitourinary Fungal Infections (Other Than Vaginal Candidiasis)

  Elsevier eBooks · 2020-02-24

  book-chapter1st authorCorresponding
  PublisherDOI

• Candidiasis and Mechanisms of Antifungal Resistance

  Antibiotics · 2020 · 462 citations

  • Microbiology
  • Biology
  • Virology

  sp.

  PublisherOA PDFDOI

• Infections in patients receiving immune checkpoint inhibitors.

  Journal of Clinical Oncology · 2019-03-10 · 3 citations

  article1st authorCorresponding

  155 Background: Immune checkpoint inhibitors (ICIs) - anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, avelumab), anti-CTLA-4 (ipilimumab) - have improved outcomes for several malignancies. ICIs may cause immune-related adverse events (irAEs), often treated with immunosuppression. The incidence of infections arising de novo during ICI therapy or from immunosuppression for irAEs is not well described. Methods: In- and outpatients receiving ICIs were referred for Infectious Diseases consultation between 6/2011-6/2018. Twenty-five were randomly selected for retrospective summarization of the spectrum of infections. Diagnosis of infection was made by the primary oncologist, based upon clinical/radiographic/laboratory data. Results: Solid tumor (24, 96%) and hematologic malignancies (1, 4%) were represented (Table). All 25 had infections. 15 (60%) were male; median age 58 years (29-97). 17 (68%) had irAEs: pneumonitis (10, 40%), thyroiditis (5, 20%), colitis (5, 20%), hepatitis (4, 16%), dermatitis (4, 16%) and myocarditis (1, 4%). 17 (68%) patients developed +1 irAE. 50% with pneumonitis were concurrently treated for pneumonia. Of the 25, 17 (72%) developed de novo infections on ICIs; whereas others were receiving systemic corticosteroids (7, 28%) or infliximab (1, 4%). Initial infections included pneumonia (13, 52%), bacteremia (3, 12%), sinusitis (2, 8%), wound infection (2, 8%), viral infections (HSV, CMV, HCV; 1, 4% each) and 1 (4%) each of empyema, UTI, peritonitis, osteomyelitis, and meningitis. 44% (11) developed a second infection within 60 days of the first. Conclusions: Patients receiving ICIs for cancer developed a myriad of infections, both de novo during ICI therapy, or consequent to immunosuppression for irAEs. Second infections are common, occurring in nearly half the patients. Awareness of this is vital for early diagnosis and appropriate management. Patients with suspected ICI-related infection. (n=25). [Table: see text]

  PublisherDOI

• Contributors

  Elsevier eBooks · 2010-01-01

  book-chapter
  PublisherDOI

• Pelvic Inflammatory Disease (Case 23)

  Elsevier eBooks · 2010-01-01

  book-chapter1st authorCorresponding
  PublisherDOI

• Ketoconazole

  2010-10-29

  book-chapter1st authorCorresponding
  PublisherDOI

• Mycobacterium avium-avium-Associated Typhlitis Mimicking Appendicitis in an Immunocompetent Host

  The American Journal of the Medical Sciences · 2009-03-01 · 4 citations

  article
  PublisherDOI

Frequent coauthors

• Dionysios Neofytos

  University Hospital of Geneva

  11 shared

• Bettina C. Fries

  Stony Brook University

  8 shared

• Aleena Zahra

  Northport VA Medical Center

  4 shared

• Jarushka Naidoo

  Royal College of Surgeons in Ireland

  4 shared

• Qingping Yao

  Stony Brook School

  4 shared

• Mark Yun

  Stony Brook School

  4 shared

• Asha Patnaik

  Stony Brook University

  4 shared

• Seema Mehta

  IIHMR University

  4 shared